Dr. Reddy's launches generic semaglutide in Canada with flexible dosing
NewsBytes | May 16, 2026 12:39 PM CST
Dr. Reddy's shares up 3%
CEO Erez Israeli called this launch part of Dr. Reddy's push to make advanced GLP-1 therapies more accessible worldwide, following a recent rollout in India under the name Obeda.
Investors seem on board: Dr. Reddy's stock ended the previous session 3% higher, capping off a solid 10% rise over the past month.
READ NEXT
-
Fish oil spill from container causes accidents on Ullal road
-
Guidelines for use of AI in medical education to be released: Official
-
Another bus gutted in fire; 36 passengers escape miraculously!
-
Telangana HC denies interim relief to Bandi Sanjay's son in POCSO case
-
How Will Hydrogen Buses Work? Find Out How They Differ from CNG and What Their Benefits Are..
